
USING SMART ALGORITHMS TO PREDICT AND PREVENT CARDIAC DISEASE

The Coala Heart Monitor uses smart sensors and algorithms to detect heart disease, linked to a secure cloud based portal for caregivers to aid their clinical evaluation.





Founded in 2015, Coala Life is a digital health venture backed by strong Swedish investors, with ~US\$12M raised to date. Based on more than a decade of R&D, the Company has commercialized a multi-award-winning portfolio of smart medical solutions focused on reducing cardiovascular fatalities, the leading cause of death.

OUR PRODUCTS & SERVICES

The Coala Heart Monitoring system is a unique digital solution to monitor and analyze the heart in real time -- anytime, anywhere. The user and patient-centric system is offered as a cloud-based subscription service in dual configurations and channels: direct to individuals and to health care professionals.

Analysis is performed in the cloud and connected to the Coala device through the Coala App where results are immediately presented to the user, as well as connected clinicians, who can access and follow their patients remotely via a dedicated web portal.

Our first solutions were launched in Sweden direct to individuals in Q1, 2017 through our online store and Lloyds Pharmacy, followed by the Coala Pro for medical professionals in Q3, 2017 to enable more efficient cardiac assessments in primary and specialty care. The company now has 100+ healthcare providers connected to the platform and thousands of users. We are continuing to commercialize our platform through leading partners such as Lloyds Pharmacy and Bayer.

WHAT MAKES US UNIQUE

Our core technology is based on synchronous ECG and heart sound recordings, coupled with smart algorithms that automatically screen for 10 different cardiac pathologies including AF. The entire solution, which comprises a CE approved Class IIa medical device, a phone app and our cloud service has been developed, manufactured and validated in Sweden. The systems are protected by multiple patent families, with additional filings in process.

The AI training data generated has the power to predict and prevent cardiac disease, and meet the vision – to help win the battle against the leading cause of death.

WHY YOU SHOULD MEET US

The Company is successfully on market and with a FDA 510(k)-clearance submission in progress. We are now looking for distribution partners and investors to scale and drive its presence and expansion primarily into the US market.

KEY TEAM

- Philip Siberg, MSc
- CEO & Co-founder
- Experienced healthcare executive with a track record of development, IPOs and sale of a number of venture-backed and public companies.
- Currently Chairman of Senzime AB; formerly CEO of Acacia Designs BV, Stille AB and CMA Microdialysis AB

Titti Lundgren, MBA

Chief Marketing
 Officer & Co-Founder

Ulf Tossman, PhD

- Medical Director, & Co-founder
- Extensive career within the Life Science industry

Magnus

- Samuelsson,MSc
- Chief Technology
 Officer
- Ex. St. Jude Medical

Johanna Tulkki, MSc

- Chief Operating Officer
- Ex. St. Jude Medical

SWEDISH AMERICAN LIFE SCIENCE SUMMIT 2018